Robert Wood Johnson University Hospital Physician Surpasses 500 Procedures Using Stereotaxis Niobe® System

ST. LOUIS, Oct. 25, 2016 -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, and Robert Wood Johnson University Hospital (RWJUH), a Cardiovascular Center of Excellence and the principal teaching hospital of the Rutgers Robert Wood Johnson Medical School, today announced that Dr. Zyad Younan has completed more than 500 cardiac ablation procedures using the Niobe^® remote magnetic navigation system. Dr. Younan currently leads the Northeast region in catheter ablations performed using the Niobe system in the six-and-a-half years since installation.

RWJUH first installed the Niobe system in 2010 and upgraded to the Niobe ES system in early 2012. Since that time, the electrophysiology lab has increased its patient caseload, through shorter procedure times, and by attracting more patients with a wide range of complex heart arrhythmias.  Collectively, the physicians of RWJUH have utilized Stereotaxis remote magnetic navigation technology in more than 1,500 procedures to date, more than any other hospital in North America from 2010 to present.

“Stereotaxis technologies are amazing innovations, and the contrasts with traditional methods are striking,” said Dr. Younan. “With the remote magnetic navigation and detailed mapping tools of the Niobe system, we are able to navigate the ablation catheter more quickly, safely, and precisely—even in hard-to-reach regions of the heart. As a result, we see decreased radiation exposure, lower risk of complications, and higher success rates, particularly for challenging procedures such as ventricular tachycardia. I believe this system will eventually become the gold standard in cardiac ablations.”    

“Stereotaxis provides yet another advanced treatment approach that is available to cardiac patients at RWJUH,” said Michael Antoniades, President and CEO of Robert Wood Johnson University Hospital.  “Our team has a well-earned reputation for expanding the boundaries of medicine while delivering cutting-edge, quality care to patients.” 

About Robert Wood Johnson University Hospital
Robert Wood Johnson University Hospital (RWJUH) is a 965-bed hospital with campuses in New Brunswick and Somerville, offering Central New Jersey residents expanded access to the highest quality medical services and a wider array of innovative therapies available at only a small number of elite academic medical centers nationwide. RWJUH has been ranked among the best hospitals in America by U.S. News & World Report six times and has been selected by the publication as a high performing hospital in several specialties. RWJ’s New Brunswick and Somerset campuses are now part of RWJBarnabas Health, the most comprehensive health care delivery system in New Jersey, treating over 3 million patients a year.

About Stereotaxis
Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. Over 100 issued patents support the Stereotaxis platform, which helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis' core Epoch^® Solution includes the Niobe^® magnetic navigation system, the Odyssey^® portfolio of lab optimization, networking and patient information management solutions, and the Vdrive^® robotic navigation system and consumables.

The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Canada, China, Japan, and elsewhere. The V-Sono™ ICE catheter manipulator, V-Loop™ variable loop catheter manipulator, and V-CAS™ catheter advancement system have received clearance in the United States, Canada, and the European Union. The V-CAS Deflect^™ catheter advancement system has been CE Marked for sale in the European Union. For more information, please visit www.stereotaxis.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness, or to obtain additional financing, in either case on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from healthcare reform in the United States, including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

Company Contact: 
Martin C. Stammer 
Chief Financial Officer
314-678-6155 

Investor Contact:
Todd Kehrli / Jim Byers  
MKR Group, Inc.
323-468-2300
[email protected]